Mexico Authorized COVID-19 Antibody Treatment for Certain People
Mexico's Federal Commission for the Protection Against Sanitary Risks (Cofepris) authorized on December 1, 2021, for emergency use the combination of bamlanivimab and etesevimab in care actions for patients with COVID-19 during the pandemic.
Cofepris licensed the combination under the therapeutic indication for treating mild to moderate coronavirus disease in adults and pediatric patients (12 years and older weighing at least 40 kilograms), with positive direct diagnostic test results for the SARS-CoV-2 virus, and who present very high-risk comorbidities that are not controlled.
As part of the approval process, experts from the New Molecules Committee held an extraordinary session. They issued a non-binding unanimous favorable opinion on the combination of drugs, which was integrated into the file submitted by Indiana-based Eli Lilly and Company.
Bamlanivimab was designed by Lilly to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19 patients.
The U.S. NIH recently published Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19.
And as of December 1, bamlanivimab and etesevimab are authorized in all U.S. states, territories, and jurisdictions.
Furthermore, healthcare providers should refer to Section 15 of the Fact Sheet for Health Care Providers for further details regarding specific variants and resistance.
Additional SARS-CoV-2 antibody treatments and news is published on this webpage.